To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

NCT02624492 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: BI 836826
DRUG: GemOx
DRUG: Rituximab
DRUG: GemOx

Sponsor

Boehringer Ingelheim